Skip to main content
PRGO
NYSE Life Sciences

Perrigo Reports $1.3B Goodwill Impairment and Cuts FY2026 EPS Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$13.6
Mkt Cap
$1.983B
52W Low
$12.17
52W High
$30.93
52W Position info
12% above low
Off High info
56% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

PRGO is trading near its 52-week low of $12.17 (12% above the low).

Summary

Perrigo Company plc announced a significant $1.3 billion goodwill impairment charge for Q4 2025 and issued a substantially reduced adjusted EPS outlook for fiscal year 2026, alongside plans for a 7% workforce reduction.


Key Events · Earnings and Guidance · PRGO

  • Goodwill Impairment

    Perrigo recognized a $1.3 billion goodwill impairment charge in Q4 2025, primarily due to a sustained decrease in share price and lower expected cash flows, particularly from its infant formula business. An additional non-cash goodwill impairment of up to $350 million may be recorded in Q1 2026.

  • Q4 2025 Adjusted EPS Miss

    Adjusted diluted EPS for Q4 2025 was $0.77, a decrease from $0.93 in the prior year, reflecting lower gross profit in infant formula and soft OTC category consumption.

  • FY 2026 Adjusted EPS Outlook Cut

    The company issued an FY2026 'All In' adjusted diluted EPS outlook of $2.00 to $2.30, a significant reduction compared to the $2.75 adjusted EPS reported for FY2025.

  • Workforce Reduction & Cost Savings

    Perrigo launched a new operational enhancement program, expecting to reduce its workforce by approximately 7% and achieve $80 million to $100 million in annualized pre-tax cost savings by the end of FY2027.


Analysis · PRGO · Life Sciences

The filing reveals a challenging financial picture for Perrigo, highlighted by a massive $1.3 billion goodwill impairment charge in Q4 2025, which significantly impacted reported earnings. This impairment, coupled with a substantial reduction in the fiscal year 2026 adjusted EPS outlook (from $2.75 in FY2025 to $2.00-$2.30), signals significant headwinds and a re-evaluation of the company's asset values and future profitability. The company's plan to reduce its workforce by approximately 7% as part of a new operational enhancement program, while aimed at cost savings, underscores the need for aggressive restructuring in response to "near-term industry pressures" and "soft consumer consumption." Investors should be concerned about the magnitude of the impairment and the lowered guidance, which suggest a difficult transition year ahead for the company.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRGO was trading at $13.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $12.17 to $30.93. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRGO - Latest Insights

PRGO
Nov 04, 2026, 12:54 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.47
Real-time Price: $16.28 info
Change: -$0.185 (-1%) info
Market Cap: $2.254B info
PRGO
Nov 04, 2026, 6:44 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $16.28 info
Change: +$0.130 (+0.80%) info
Market Cap: $2.254B info
PRGO
Nov 04, 2026, 6:41 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $16.28 info
Change: +$0.130 (+0.80%) info
Market Cap: $2.254B info
PRGO
Nov 04, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.70
Real-time Price: $16.28 info
Change: +$0.580 (+4%) info
Market Cap: $2.254B info
PRGO
Oct 29, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.95
Real-time Price: $16.28 info
Change: +$0.330 (+2%) info
Market Cap: $2.254B info